Neurocrine Biosciences Q3 EPS Beats by $0.59 on 27.8% Sales Growth, Target Raised to $200
Neurocrine Biosciences reported Q3 EPS of $2.17, topping consensus by $0.59 on $794.9M revenue, up 27.8% year-over-year. TD Cowen increased its price target from $175 to $200 and maintained a Buy rating on the stock.
1. Cerity Partners Significantly Boosts Stake
Cerity Partners LLC increased its holdings in Neurocrine Biosciences by 76.3% during the third quarter, acquiring an additional 44,852 shares and bringing its total to 103,626 shares. This stake represented approximately 0.10% of the company and was valued at $14.55 million at quarter end, underscoring Cerity’s bullish outlook on Neurocrine’s long-term growth potential in neurological and neuropsychiatric therapies.
2. Broad Institutional Interest Intensifies
Other institutional investors also expanded positions in Neurocrine during the first quarter. Royal Bank of Canada purchased 22,224 shares to reach a holding of 82,810 shares, Integrated Wealth Concepts LLC added 4,526 shares to total 7,233, and MIRAE Asset Global ETFS Holdings Ltd. acquired 5,577 shares to own 14,783. NewEdge Advisors LLC and Empowered Funds LLC added 2,747 shares and initiated a new position of approximately $1.33 million, respectively. Collectively, institutions now own over 92% of the company’s shares, reflecting strong confidence in its clinical pipeline and commercial-stage products.
3. Analysts Maintain Upbeat Ratings
Seventeen research firms have assigned Buy ratings to Neurocrine while six have issued Holds, resulting in an average consensus of Moderate Buy. Following recent presentations at the 44th Annual J.P. Morgan Healthcare Conference, TD Cowen elevated its rating to Buy and raised its target to $200, and Royal Bank of Canada reiterated an Outperform call with an increased target of $180. Morgan Stanley affirmed an Equal Weight stance with a marginal target increase. Wedbush and Weiss Ratings maintained their Outperform and Hold (C+) views, respectively, indicating broad analyst support for Neurocrine’s revenue growth trajectory.
4. Insider Sales Reflect Portfolio Realignment
Senior executives reduced their direct shareholdings in December. Darin Lippoldt sold 4,376 shares, trimming his stake by 9.2% to a post-transaction holding of 43,405 shares. Director Leslie V. Norwalk disposed of 1,190 shares, a 16.0% reduction, leaving 6,239 shares under her ownership. Over the past 90 days, insiders have collectively sold 43,866 shares, representing 4.8% of total insider ownership, signaling a strategic reallocation rather than a fundamental shift in confidence given the company’s robust earnings growth and pipeline milestones.